|
楼主 |
发表于 2009-4-3 22:11:12
|
显示全部楼层
来自: 中国北京
原帖由 ganyedesx 于 2009-4-3 19:39 发表
passion你好,我母亲非小细胞肺腺癌接受过四次铂类化疗,后来服用易瑞沙一年(六个月后赠药),现在已经耐药了,胸腔和心包有积液,昨天刚进行胸腔穿刺引流。面对现在这种危机时刻非常想加入BIBW2992临床实验,麻烦p ...
别着急,我抄的电话是肿瘤医院就诊卡上的,你问下114应该就可以。实在不好意思,我上次去的时候因为只是开保肝药,去了胸科(东肿瘤胸内胸外在一起分诊),护士让我去一个人最少的5诊室(对不起没非常注意是胸内还是胸外,依稀记得是胸外?右手边的走廊),我就进去了...连人名也没看清楚...要不你再打电话过去问问?
你也可以去看美国clinical trial 的网站,http://clinicaltrials.gov/ct2/show/NCT00656136?show_locs=Y,试验刚开始,但是是与安慰剂随机双盲的 - 对病人还是有很大风险的!
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed. The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment.
条件貌似很苛刻:
Exclusion Criteria:不适合的患者
Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of treatment Day 1 Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks
Active brain metastases
Significant or recent acute gastrointestinal disorders with diarrhea
Patients who have any other life-threatening illness or organ system dysfunction,
Other malignancies diagnosed within the past five (5) years
Radiotherapy within the past 2 weeks prior to treatment
History of clinically significant or uncontrolled cardiac disease
Adequate ANC and platelet count
Adequate liver and kidney function
Patients with any serious active infection including known HIV, active hepatitis B or active hepatitis C
[ 本帖最后由 passion 于 2009-4-3 22:13 编辑 ] |
|